162 related articles for article (PubMed ID: 36661240)
1. Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19.
Taiwo BO; Chew KW; Moser C; Wohl DA; Daar ES; Li JZ; Greninger AL; Bausch C; Luke T; Hoover K; Neytman G; Giganti MJ; Olefsky M; Javan AC; Fletcher CV; Eron JJ; Currier JS; Hughes MD; Smith DM;
J Infect Dis; 2023 Jul; 228(2):133-142. PubMed ID: 36661240
[TBL] [Abstract][Full Text] [Related]
2. One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial.
Jilg N; Chew KW; Giganti MJ; Daar ES; Wohl DA; Javan AC; Kantor A; Moser C; Coombs RW; Neytman G; Hoover K; Jana A; Hart PA; Greninger AL; Szurgot B; Eron JJ; Currier JS; Hughes MD; Smith DM; Li JZ;
Clin Infect Dis; 2023 Oct; 77(7):941-949. PubMed ID: 37279602
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials.
Bender Ignacio RA; Chew KW; Moser C; Currier JS; Eron JJ; Javan AC; Giganti MJ; Aga E; Gibbs M; Tchouakam Kouekam H; Johnsson E; Esser MT; Hoover K; Neytman G; Newell M; Daar ES; Fischer W; Fletcher CV; Li JZ; Greninger AL; Coombs RW; Hughes MD; Smith D; Wohl DA;
JAMA Netw Open; 2023 Apr; 6(4):e2310039. PubMed ID: 37099295
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial.
Maranda B; Labbé SM; Lurquin M; Brabant P; Fugère A; Larrivée JF; Grbic D; Leroux A; Leduc F; Finzi A; Gaudreau S; Swart Y;
Lancet Infect Dis; 2024 Jan; 24(1):25-35. PubMed ID: 37619584
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adults.
Jin Z; Wu J; Wang Y; Huang T; Zhao K; Liu J; Wang H; Zhu T; Gou J; Huang H; Wu X; Yin H; Song J; Li R; Zhang J; Li L; Chen J; Li X; Zhang M; Li J; Hou M; Song Y; Wang B; Gao Q; Wu L; Kong Y; Dong R
J Infect; 2023 Dec; 87(6):556-570. PubMed ID: 37898410
[TBL] [Abstract][Full Text] [Related]
8. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM
JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701
[TBL] [Abstract][Full Text] [Related]
9. Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19.
Giganti MJ; Chew KW; Eron JJ; Li JZ; Pinilla M; Moser C; Javan AC; Fischer WA; Klekotka P; Margolis D; Wohl DA; Coombs RW; Daar ES; Smith DM; Currier JS; Hughes MD;
J Infect Dis; 2023 Aug; 228(Suppl 2):S117-S125. PubMed ID: 37650230
[TBL] [Abstract][Full Text] [Related]
10. Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical Trial.
Chew KW; Moser C; Daar ES; Wohl DA; Li JZ; Coombs R; Ritz J; Giganti M; Javan AC; Li Y; Malvestutto C; Klekotka P; Price K; Nirula A; Fischer W; Bala V; Ribeiro RM; Perelson AS; Fletcher CV; Eron JJ; Currier JS; Hughes MD; Smith DM;
medRxiv; 2021 Dec; ():. PubMed ID: 34981077
[TBL] [Abstract][Full Text] [Related]
11. Ivermectin for preventing and treating COVID-19.
Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
[TBL] [Abstract][Full Text] [Related]
12. A Phase 2 Randomized Trial Evaluating the Antiviral Activity and Safety of the Direct-Acting Antiviral Bemnifosbuvir in Ambulatory Patients with Mild or Moderate COVID-19 (MOONSONG Study).
Boffito M; Dolan E; Singh K; Holmes W; Wildum S; Horga A; Pietropaolo K; Zhou XJ; Clinch B; Collinson N; Ukachukwu V
Microbiol Spectr; 2023 Aug; 11(4):e0007723. PubMed ID: 37338393
[TBL] [Abstract][Full Text] [Related]
13. Hyperimmune immunoglobulin for people with COVID-19.
Kimber C; Valk SJ; Chai KL; Piechotta V; Iannizzi C; Monsef I; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD015167. PubMed ID: 36700518
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.
Evering TH; Chew KW; Giganti MJ; Moser C; Pinilla M; Wohl DA; Currier JS; Eron JJ; Javan AC; Bender Ignacio R; Margolis D; Zhu Q; Ma J; Zhong L; Yan L; D'Andrea Nores U; Hoover K; Mocherla B; Choudhary MC; Deo R; Ritz J; Fischer WA; Fletcher CV; Li JZ; Hughes MD; Smith D; Daar ES;
Ann Intern Med; 2023 May; 176(5):658-666. PubMed ID: 37068272
[TBL] [Abstract][Full Text] [Related]
15. Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19.
Martin DE; Pandey N; Chavda P; Singh G; Sutariya R; Sancilio F; Tripp RA
Viruses; 2023 Jul; 15(7):. PubMed ID: 37515194
[TBL] [Abstract][Full Text] [Related]
16. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
17. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
Jayk Bernal A; Gomes da Silva MM; Musungaie DB; Kovalchuk E; Gonzalez A; Delos Reyes V; Martín-Quirós A; Caraco Y; Williams-Diaz A; Brown ML; Du J; Pedley A; Assaid C; Strizki J; Grobler JA; Shamsuddin HH; Tipping R; Wan H; Paschke A; Butterton JR; Johnson MG; De Anda C;
N Engl J Med; 2022 Feb; 386(6):509-520. PubMed ID: 34914868
[TBL] [Abstract][Full Text] [Related]
18. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
19. Olgotrelvir as a Single-Agent Treatment of Nonhospitalized Patients with Covid-19.
Jiang R; Han B; Xu W; Zhang X; Peng C; Dang Q; Sun W; Lin L; Lin Y; Fan L; Lv D; Shao L; Chen Y; Qiu Y; Han L; Kong W; Li G; Wang K; Peng J; Lin B; Tong Z; Lu X; Wang L; Gao F; Feng J; Li Y; Ma X; Wang J; Wang S; Shen W; Wang C; Yan K; Lin Z; Jin C; Mao L; Liu J; Kushnareva Y; Kotoi O; Zhu Z; Royal M; Brunswick M; Ji H; Xu X; Lu H
NEJM Evid; 2024 Jun; 3(6):EVIDoa2400026. PubMed ID: 38804790
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]